Suppr超能文献

更正：依维莫司（EVE）与依西美坦（EXE）用于年龄≥65岁的晚期乳腺癌患者：EVA研究为临床实践带来的新启示。

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.

作者信息

Cazzaniga Marina, Verusio Claudio, Ciccarese Mariangela, Fumagalli Alberto, Sartori Donata, Valerio Maria Rosaria, Airoldi Mario, Moretti Gabriella, Ficorella Corrado, Arcangeli Valentina, Diodati Lucrezia, Zambelli Alberto, Febbraro Antonio, Generali Daniele, Pistelli Mirco, Garrone Ornella, Musolino Antonino, Vici Patrizia, Maur Michela, Mentuccia Lucia, La Verde Nicla, Bianchi Giulia, Artale Salvatore, Blasi Livio, Piezzo Matilde, Atzori Francesco, Turletti Anna, Benedetto Chiara, Cursano Maria Concetta, Fabi Alessandra, Gebbia Vittorio, Schirone Alessio, Palumbo Raffaella, Ferzi Antonella, Frassoldati Antonio, Scavelli Claudio, Clivio Luca, Torri On Behalf Of The Eva Study Group Valter

机构信息

Research Unit Phase I trials, ASST Monza, Monza, Italy.

Oncology Unit, ASST Monza, Monza, Italy.

出版信息

Oncotarget. 2018 Oct 2;9(77):34639-34640. doi: 10.18632/oncotarget.26213.

DOI:10.18632/oncotarget.26213
PMID:30349655
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6195381/
Abstract

[This corrects the article DOI: 10.18632/oncotarget.25874.].

摘要

[本文更正了文章的数字对象标识符：10.18632/oncotarget.25874。]

相似文献

1
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.更正：依维莫司（EVE）与依西美坦（EXE）用于年龄≥65岁的晚期乳腺癌患者：EVA研究为临床实践带来的新启示。
Oncotarget. 2018 Oct 2;9(77):34639-34640. doi: 10.18632/oncotarget.26213.
2
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.更正2：依维莫司（EVE）与依西美坦（EXE）用于≥65岁晚期乳腺癌患者：EVA研究为临床实践带来的新启示
Oncotarget. 2018 Nov 30;9(94):36720-36721. doi: 10.18632/oncotarget.26431.
3
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.依维莫司联合依西美坦治疗激素受体阳性（HR+）人表皮生长因子受体阴性（HER2-）晚期乳腺癌患者的疗效和安全性：临床试验以外的新见解。EVA 研究。
Breast. 2017 Oct;35:115-121. doi: 10.1016/j.breast.2017.06.043. Epub 2017 Jul 13.
4
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.依维莫司（EVE）与依西美坦（EXE）用于≥65岁晚期乳腺癌患者：EVA研究给临床实践带来的新启示
Oncotarget. 2018 Aug 7;9(61):31877-31887. doi: 10.18632/oncotarget.25874.
5
Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.在西欧晚期乳腺癌患者中，依维莫司联合依西美坦或单药化疗治疗期间不良事件的成本。
J Med Econ. 2014 Dec;17(12):837-45. doi: 10.3111/13696998.2014.959589. Epub 2014 Sep 18.
6
Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2- Advanced Breast Cancer From a US Payer Perspective.从美国医保支付方角度看依维莫司与其他激素疗法治疗HR+/HER2-晚期乳腺癌的经济学评估
Clin Breast Cancer. 2015 Oct;15(5):e263-76. doi: 10.1016/j.clbc.2015.04.001. Epub 2015 Apr 23.
7
Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.依维莫司联合依西美坦对比贝伐单抗为基础的化疗用于希腊激素受体阳性转移性乳腺癌二线治疗的经济学评估研究
BMC Health Serv Res. 2015 Aug 5;15:307. doi: 10.1186/s12913-015-0971-4.
8
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.依维莫司联合依西美坦对比化疗用于雌激素受体阳性转移性乳腺癌一线及二线治疗的网状Meta分析
Breast Cancer Res Treat. 2015 Jul;152(1):95-117. doi: 10.1007/s10549-015-3453-9. Epub 2015 Jun 5.
9
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.依维莫司与依西美坦联合用药（EVE/EXE）在激素受体阳性（ER+/PgR+）、HER2阴性晚期乳腺癌（ABC）患者真实世界人群中的剂量强度和疗效：一项意大利多中心经验。
Breast Cancer Res Treat. 2017 Jun;163(3):587-594. doi: 10.1007/s10549-017-4213-9. Epub 2017 Mar 28.
10
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.依维莫司联合依西美坦治疗晚期乳腺癌：BALLET研究中既往在转移情况下未接受化疗和接受化疗患者的安全性结果
Oncologist. 2017 Jun;22(6):648-654. doi: 10.1634/theoncologist.2016-0461. Epub 2017 Apr 21.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验